FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer

1 year ago 53

The FDA has received a type C meeting request from Oncolytics Biotech to discuss a registration-enabling trial for pelareorep in HR+/HER2– breast cancer.

1. Homepage
2. Breast Cancer
3. FDA Receives Type C Meeting Request for Pelareorep in HR+/HER2– Metastatic Breast Cancer